Literature DB >> 22845052

Pharmacokinetics of paracetamol and its metabolites in women at delivery and post-partum.

Aida Kulo1, Mariska Y Peeters, Karel Allegaert, Anne Smits, Jan de Hoon, Rene Verbesselt, Liesbeth Lewi, Marc van de Velde, Catherijne A J Knibbe.   

Abstract

AIM: A recent report on intravenous (i.v.) paracetamol pharmacokinetics (PK) showed a higher total clearance in women at delivery compared with non-pregnant women. To describe the paracetamol metabolic and elimination routes involved in this increase in clearance, we performed a population PK analysis in women at delivery and post-partum in which the different pathways were considered.
METHODS: Population PK parameters using non-linear mixed effect modelling were estimated in a two-period PK study in women to whom i.v. paracetamol (2 g loading dose followed by 1 g every 6 h up to 24 h) was administered immediately following Caesarean delivery and in a subgroup of the same women to whom single 2 g i.v.loading dose was administered 10-15 weeks post-partum.
RESULTS: Population PK analysis was performed based on 255 plasma and 71 urine samples collected in 39 women at delivery and in eight of these 39 women 12 weeks post-partum. Total clearance was higher in women at delivery compared with 12th post-partum week (21.1 vs. 11.7 l h⁻¹) due to higher clearances to paracetamol glucuronide (11.6 vs. 4.76 l h⁻¹), to oxidative metabolites (4.95 vs. 2.77 l h⁻¹) and of unchanged paracetamol (1.15 vs. 0.75 l h⁻¹). In contrast, there was no difference in clearance to paracetamol sulphate.
CONCLUSION: The increased total paracetamol clearance at delivery is caused by a disproportional increase in glucuronidation clearance and a proportional increase in clearance of unchanged paracetamol and in oxidation clearance, of which the latter may potentially limit further dose increase in this patient group.
© 2012 The Authors. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22845052      PMCID: PMC3575952          DOI: 10.1111/j.1365-2125.2012.04402.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  28 in total

Review 1.  Mechanisms of renal vasodilation and hyperfiltration during pregnancy.

Authors:  Kirk P Conrad
Journal:  J Soc Gynecol Investig       Date:  2004-10

2.  Pharmacokinetics of a loading dose of intravenous paracetamol post caesarean delivery.

Authors:  A Kulo; M van de Velde; J de Hoon; R Verbesselt; R Devlieger; J Deprest; K Allegaert
Journal:  Int J Obstet Anesth       Date:  2012-02-15       Impact factor: 2.603

3.  Glomerular heteroporous membrane modeling in third trimester and postpartum before and during amino acid infusion.

Authors:  J E C Milne; M D Lindheimer; J M Davison
Journal:  Am J Physiol Renal Physiol       Date:  2002-01

4.  Pharmacokinetics of acetaminophen elimination by anephric patients.

Authors:  D T Lowenthal; S Oie; J C Van Stone; W A Briggs; G Levy
Journal:  J Pharmacol Exp Ther       Date:  1976-03       Impact factor: 4.030

Review 5.  Inhibition of human liver and duodenum sulfotransferases by drugs and dietary chemicals: a review of the literature.

Authors:  G M Pacifici
Journal:  Int J Clin Pharmacol Ther       Date:  2004-09       Impact factor: 1.366

6.  Paracetamol metabolism in pregnancy.

Authors:  J O Miners; R A Robson; D J Birkett
Journal:  Br J Clin Pharmacol       Date:  1986-09       Impact factor: 4.335

7.  Platelet phenol sulfotransferase activity: correlation with sulfate conjugation of acetaminophen.

Authors:  C Reiter; R Weinshilboum
Journal:  Clin Pharmacol Ther       Date:  1982-11       Impact factor: 6.875

8.  Paracetamol glucuronidation by recombinant rat and human phenol UDP-glucuronosyltransferases.

Authors:  K W Bock; A Forster; H Gschaidmeier; M Brück; P Münzel; W Schareck; S Fournel-Gigleux; B Burchell
Journal:  Biochem Pharmacol       Date:  1993-05-05       Impact factor: 5.858

9.  Intravenous paracetamol (propacetamol) pharmacokinetics in term and preterm neonates.

Authors:  Karel Allegaert; Brian J Anderson; Gunnar Naulaers; Jan de Hoon; Rene Verbesselt; Anne Debeer; Hugo Devlieger; Dick Tibboel
Journal:  Eur J Clin Pharmacol       Date:  2004-04-08       Impact factor: 2.953

10.  Analgesic effect of i.v. paracetamol: possible ceiling effect of paracetamol in postoperative pain.

Authors:  T W Hahn; T Mogensen; C Lund; L S Jacobsen; N-C Hjortsoe; S N Rasmussen; M Rasmussen
Journal:  Acta Anaesthesiol Scand       Date:  2003-02       Impact factor: 2.105

View more
  21 in total

1.  The impact of pregnancy on urinary ketorolac metabolites after single intravenous bolus.

Authors:  Aida Kulo; Sarah Hendrickx; Jan de Hoon; Nedzad Mulabegovic; Kristel van Calsteren; Rene Verbesselt; Karel Allegaert
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2012-11-21       Impact factor: 2.441

2.  Pharmacokinetics of dacarbazine (DTIC) in pregnancy.

Authors:  Ira Kantrowitz-Gordon; Karen Hays; Olumide Kayode; Aditya R Kumar; Henry G Kaplan; Joel M Reid; Stephanie L Safgren; Matthew M Ames; Thomas R Easterling; Mary F Hebert
Journal:  Cancer Chemother Pharmacol       Date:  2018-01-05       Impact factor: 3.333

3.  A Physiologically Based Pharmacokinetic Model for Pregnant Women to Predict the Pharmacokinetics of Drugs Metabolized Via Several Enzymatic Pathways.

Authors:  André Dallmann; Ibrahim Ince; Katrin Coboeken; Thomas Eissing; Georg Hempel
Journal:  Clin Pharmacokinet       Date:  2018-06       Impact factor: 6.447

4.  Enantiomer-specific ketorolac pharmacokinetics in young women, including pregnancy and postpartum period.

Authors:  Aida Kulo; Anne Smits; Sanita Maleškić; Marc Van de Velde; Kristel Van Calsteren; Jan De Hoon; Rene Verbesselt; Jan Deprest; Karel Allegaert
Journal:  Bosn J Basic Med Sci       Date:  2017-02-21       Impact factor: 3.363

5.  Neonatal Maturation of Paracetamol (Acetaminophen) Glucuronidation, Sulfation, and Oxidation Based on a Parent-Metabolite Population Pharmacokinetic Model.

Authors:  Sarah F Cook; Chris Stockmann; Samira Samiee-Zafarghandy; Amber D King; Nina Deutsch; Elaine F Williams; Diana G Wilkins; Catherine M T Sherwin; John N van den Anker
Journal:  Clin Pharmacokinet       Date:  2016-11       Impact factor: 6.447

6.  Evaluation of changes in oral drug absorption in preterm and term neonates for Biopharmaceutics Classification System (BCS) class I and II compounds.

Authors:  Amit A Somani; Kirstin Thelen; Songmao Zheng; Mirjam N Trame; Katrin Coboeken; Michaela Meyer; Katrin Schnizler; Ibrahim Ince; Stefan Willmann; Stephan Schmidt
Journal:  Br J Clin Pharmacol       Date:  2015-10-30       Impact factor: 4.335

Review 7.  Basic obstetric pharmacology.

Authors:  Yang Zhao; Mary F Hebert; Raman Venkataramanan
Journal:  Semin Perinatol       Date:  2014-10-01       Impact factor: 3.300

8.  Developmental changes rather than repeated administration drive paracetamol glucuronidation in neonates and infants.

Authors:  Elke H J Krekels; Saskia van Ham; Karel Allegaert; Jan de Hoon; Dick Tibboel; Meindert Danhof; Catherijne A J Knibbe
Journal:  Eur J Clin Pharmacol       Date:  2015-07-03       Impact factor: 2.953

9.  Human placental lactogen induces CYP2E1 expression via PI 3-kinase pathway in female human hepatocytes.

Authors:  Jin Kyung Lee; Hye Jin Chung; Liam Fischer; James Fischer; Frank J Gonzalez; Hyunyoung Jeong
Journal:  Drug Metab Dispos       Date:  2014-01-09       Impact factor: 3.922

Review 10.  Ontogeny of Drug-Metabolizing Enzymes.

Authors:  Aarzoo Thakur; Md Masud Parvez; J Steven Leeder; Bhagwat Prasad
Journal:  Methods Mol Biol       Date:  2021
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.